<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">GOMEZ-FLORES, RICARDO</style></author><author><style face="normal" font="default" size="100%">CABALLERO-HERNANDEZ, DIANA</style></author><author><style face="normal" font="default" size="100%">TAMEZ-GUERRA, REYES</style></author><author><style face="normal" font="default" size="100%">RODRIGUEZ-PADILLA, CRISTINA</style></author><author><style face="normal" font="default" size="100%">TAMEZ-GUERRA, PATRICIA</style></author><author><style face="normal" font="default" size="100%">RICE, KENNER C.</style></author><author><style face="normal" font="default" size="100%">HICKS, MARY E.</style></author><author><style face="normal" font="default" size="100%">WEBER, RICHARD J.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Increased Survival of Tumor-bearing Mice by the Delta Opioid SNC 80</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4563-4567</style></pages><volume><style face="normal" font="default" size="100%">25</style></volume><issue><style face="normal" font="default" size="100%">6C</style></issue><abstract><style  face="normal" font="default" size="100%">Opioids represent a major source of relief from pain. However, opioid abuse may cause immunosuppression and cancer. We have recently reported results on novel non-peptidic delta- and mu-selective opioids that induced immunopotentiation of T cell and macrophage functions in vitro and ex vivo. In the present study, the effects of the delta-opioid receptor agonist and potent analgesic (+)-4-((alpha R)-alpha-((2S, 5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N, N-diethyl-benzamide (SNC80) on in vitro and in vivo tumor cell growth were investigated using the L5178Y-R murine model. SNC80 marginally, but significantly (p&lt;0.05), inhibited (up to 14%) the in vitro growth of L5178Y-R tumor cells. However, in vivo intratumor administration of SNC80 (2 and 4 mg/kg) reduced up to 60% L5178Y-R tumor-bearing Balb/c mice death, and significantly (p&lt;0.05) reduced tumor weights (up to 73% reduction) in these animals. This study may support the evaluation of SNC80 in preclinical and clinical studies. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved</style></abstract></record></records></xml>